Regenerative Medicine Essentials Course

Course Instructors

The 2017 Regenerative Medicine Essentials course will feature prominent members of the Wake Forest Institute for Regenerative Medicine (WFIRM) faculty along with distinguished invited guests. See the list of course instructors below and click on their names to see detailed bios. 

Anthony Atala, MD
Director, Wake Forest Institute for Regenerative Medicine

Julie Allickson, PhD
Director, Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine

Graca Almeida-Porada, MD, PhD
Professor, Wake Forest Institute for Regenerative Medicine

Guillermo Ameer, PhD
Professor, Biomedical Engineering and Department of Surgery at the Feinberg School of Medicine, Northwestern University

Daniel G. Anderson, PhD
Department of Chemical Engineering, Institute for Medical Engineering and Science, Harvard-MIT Division of Health Sciences and Technology; David H. Koch Institute for Integrative Cancer Research 

Arnold Caplan, PhD
Professor, Departments of Biology, General Medical Sciences (Oncology), Pathology, and Biomedical Engineering, Case Western Reserve University; Founder of Osiris Therapeutic

Gabor Forgacs, PhD
Professor of Biological Physics, University of Missouri-Columbia; Chief Scientific Officer, Modern Meadows, Inc.

Beth Fordham-Meier
Principal and Founder, NovoCreation Consulting, LLC

Rosemarie Hunziker, PhD
Director of Tissue Engineering and Regenerative Medicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB)

John Jackson, PhD
Associate Professor, Wake Forest Institute for Regenerative Medicine

Nancy King, JD
Co-Director, Center for Bioethics, Health and Society, Wake Forest University

Joanne Kurtzberg, MD
Director, Pediatric Blood and Marrow Transplant Program, Duke University Medical Center

Jeanne F. Loring, PhD
Professor of Developmental Neurobiology, Director of the Center for Regenerative Medicine, Department of Chemical Physiology, California Campus, The Scripps Research Institute

Frank Marini, PhD
Professor, Wake Forest Institute for Regenerative Medicine

Antonios G. Mikos, PhD
Louis Calder Professor of Bioengineering, Chemical and Biomolecular Engineering, Director for Center for Excellence in Tissue Engineering, Director for J.W. Cox Laboratory for Biomedical Engineering, Rice University 

C. Randal Mills, PhD
President & CEO, California Institute for Regenerative Medicine (CIRM)

Sean Murphy, PhD
Assistant Professor, Wake Forest Institute for Regenerative Medicine

Daniel K. Nelson, MS, CIP
Professor and Director of U.S. Environmental Protection Agency and University of North Carolina - Chapel Hill

Steven Oh, PhD
Chief, Cell Therapies; Office of Tissues and Advanced Therapies, FDA, CBER

Chris Porada, PhD
Associate Professor, Wake Forest Institute for Regenerative Medicine 

Robert Preti
Chairman, Alliance for Regenerative Medicine; Director, Caladrius Biosciences

Becky Robinson-Zeigler, PhD
Chief of Pharmacology/Toxicology Branch 2 in CBER/OTAT

Aleksander Skardal, PhD
Assistant Professor, Wake Forest Institute for Regenerative Medicine

Igor Slukvin, MD, PhD
Professor, Department of Pathology and Laboratory Medicine, University of Wisconsin

Doris A. Taylor, PhD, FAHA, FACC
Director, Regenerative Medicine Research, Texas Heart Institute; Director, Center for Cell and Organ Biotechnology at Texas Heart Institute and TAMU College of Veterinary Medicine; Adjunct Professor, TAMU College of Veterinary Medicine, Dept. of Veterinary Physiology and Pharmacology; Adjunct Professor, Dept. of Biosciences, Rice University

Omid Veiseh, PhD
Assistant Professor of Bioengineering, CPRIT Scholar in Cancer Research, Rice University

Julie Watson, JD
Special Counsel, Marshall, Gerstein & Borun, LLP; Intellectual Property Director and Legal Counsel, WFIRM

David Williams, DSc
Professor and Director of International Affairs, Wake Forest Institute for Regenerative Medicine

James J. Yoo, MD, PhD
Associate Director and Chief Scientific Officer, WFIRM

 

Course Instructors

 

Anthony_Atala_0509A.jpgAnthony Atala, MD
Director, Wake Forest Institute for Regenerative Medicine

Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. His work focuses on growing human cells, tissues and organs. Dr. Atala works with several journals and serves in various roles, including Editor-in-Chief of: Stem Cells- Translational Medicine; Current Stem Cell Research and Therapy; Therapeutic Advances in Urology; and BioPrinting. Dr. Atala is a recipient of awards, including the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, the World Technology Award in Health and Medicine, the Samuel D. Gross Prize in Surgical Research, the Innovation Award from the Society of Manufacturing Engineers, the Rocovich Gold Medal, and the Edison Science/Medical Award for work in 3D Bioprinting. In 2011 he was elected to the Institute of Medicine of the National Academy of Sciences, and in 2014 was inducted to the National Academy of Inventors as a Charter Fellow. Dr. Atala’s ongoing work has been described in the lay press. Dr. Atala’s work was listed in 2007 as Time Magazine’s top 10 medical breakthroughs of the year, by Discover Magazine in 2007 as the Number 1 Top Science Story of the Year in the field of medicine, by Smithsonian Magazine in 2010 as one of 40 things to know about the next 40 years, by Time Magazine in 2011 as one of the top 5 medical breakthroughs of the year, by the Huffington post in 2011 as one of 18 great ideas for the future, and by Time Magazine in 2013 as one of 5 discoveries that will change the future of organ transplants. Dr. Atala was named by Scientific American in 2010 as a Medical Treatments Leader of the Year for his contributions to the fields of cell, tissue and organ regeneration, by U.S. News & World Report in 2009 in as one of 14 Pioneers of Medical Progress in the 21st Century, by the American Association of Retired Persons in 2012 as one of the 50 influential people who will make life better, and by Scientific American in 2015 as one of the world’s most influential people in biotechnology. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the Bioengineering Consortium, the National Cancer Institute’s National Cancer Advisory Board, and was the Founder of the Regenerative Medicine Foundation. Dr. Atala heads a team of over 450 physicians and researchers. Over twelve applications of technologies developed in Dr. Atala’s laboratory have been used clinically. He is the editor of fourteen books, including Principles of Regenerative Medicine, 3D Biofabrication, Essentials of Stem Cell Biology, and Methods of Tissue Engineering. He has published more than 500 journal articles and has applied for or received over 250 national and international patents. Back to top.

 


 

Julie AllicksonJulie Allickson, PhD
Director, Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine

Julie Allickson focuses on the translation of regenerative medicine products including cell therapy, tissue engineering, biomaterials and devices. This process begins at Proof-of-Concept where early discussion with regulators and clinicians are critical in moving the technology from the bench to the bedside. The Translational Team includes Quality Assurance, Quality Control, Regulatory Affairs, Process Development and the GMP-complaint Manufacturing Facility. Prior to joining the institute, she was an Executive Officer of the company and Vice President of Laboratory Operations and R & D at Cryo-Cell International, Inc., an AABB accredited Cord Blood Bank.

As Vice President of the Laboratory Dr. Allickson was responsible for all technical aspects of Laboratory Operations along with Research and Development activities associated with adult stem cells, including the development work related to isolation of a unique stem cell harvested from menstrual blood. Prior to this position, Dr. Allickson worked for the University Of Miami School Of Medicine, Diabetes Research Institute as the Laboratory Director of the cGMP Hematopoietic Cell Processing Facility. She was responsible for the design and implementation of the State Licensed Clinical Flow Cytometry Laboratory. Dr. Allickson was the lead in Regulatory Affairs for the processing laboratory of Islet and Hematopoietic Cell products which included oversight of all Investigational New Drugs (IND) and external regulations.

Prior to working for the University of Miami she worked for the American Red Cross managing the Hematopoietic Cell Processing and Platelet Serology Laboratory. During her tenure at the American Red Cross she served as a member of the National Stem Cell Task Force and participated in the preparation of national protocols developed for Hematopoietic Cell Processing Laboratories. Dr. Allickson was part of the team to perform the very first Bone Marrow Transplant at the University of Miami in 1990.

Dr. Allickson has 25 years experience in Cellular Therapy, Cellular Processing and Regenerative Medicine. She has a Doctorate in Health Sciences along with a Master's Degree in Medical Laboratory Sciences. She is one of the founding members of the International Society of Cellular Therapy in 1992 and has been a member of the American Association of Blood Banks (AABB) for 25 years. She has presented at national and international meeting related to adult stem cells and translation. She is currently Chair of the AABB Standards Committee for Cell Therapy Product Services. Dr. Allickson is also on the Technical Advisory Board for Tissue Engineered Products under ICCBBA and the ISCT Commercialization Committee. Back to top.

 


 

Almeida PoradoGraca Almeida-Porada, MD, PhD
Professor, Wake Forest Institute for Regenerative Medicine

Dr. Almeida-Porada was born and raised in Portugal. She received her medical degree in 1986 from the Instituto de Ciências Biomédicas Abel Salazar (ICBAS) of University of Porto, Portugal. She completed her residency and fellowship in Hematology/Transfusion Medicine at University Hospital of Santo Antonio, and obtained her Ph.D. in Pathology from ICBAS in 1995. She was a fellow at the University of Connecticut Health Center and at the University of Nevada, Reno School of Medicine. She became faculty at the University of Nevada, Reno in 1999. In 2001 she joined the Department of Animal Biotechnology at the same Institution, where she was a Professor and the Director of Graduate Studies. In 2006 she was inducted into Phi Beta Delta. She serves on the Editorial Boards of several scientific journals, and was an Associate Editor for Experimental Hematology. Dr. Almeida-Porada has authored more than 90 scientific publications and reviews, and has written chapters in several books. She joined the faculty at WFIRM in 2011. Back to top.

 


 

Ameer HeadshotGuillermo Ameer, PhD
Professor, Biomedical Engineering and Department of Surgery at the Feinberg School of Medicine, Northwestern University

Dr. Ameer is a professor in the Biomedical Engineering Department at the McCormick School of Engineering and the Department of Surgery at the Feinberg School of Medicine, Northwestern University. He is also a resident faculty member at the Simpson-Querrey Institute for BioNanotechnology, a member of the Chemistry of Life Processes Institute, and the International Institute for Nanotechnology. Dr. Ameer received an Associate of Science degree from Collin County Community College in Plano Texas, his Bachelor’s degree in Chemical Engineering from the University of Texas at Austin, and his doctoral degree in Chemical and Biomedical Engineering from the Massachusetts Institute of Technology. His research interests include biomaterials, tissue engineering, regenerative engineering, on demand, patient-specific medical devices, controlled drug delivery and bio/nanotechnology for improved therapeutics and diagnostics. Specifically, Dr. Ameer’s laboratory pioneered the development and applications of citric acid-based biomaterials. He has co-authored over 250 peer-reviewed journal publications and conference abstracts, several book chapters, and over 40 patents issued and pending in 9 countries, several of which have been licensed to develop innovative medical products. Dr. Ameer has received numerous awards, including election to Technology Review Magazine's top 100 Young Innovators in the world, the NSF CAREER award, and the American Heart Association's Established Investigator Award, and the American Institute of Chemical Engineers’ MAC Eminent Chemical Engineer Award.  He has served on several national and international scientific review committees for funding research.  He was elected Fellow of the American Institute of Medical and Biological Engineering and of the Biomedical Engineering Society. Dr. Ameer is currently a member of the Board of Directors of the Biomedical Engineering Society and co-chair of the Diversity Committee. Dr. Ameer is an Associate Editor for the journal Regenerative Engineering and Translational Medicine and he is on the editorial boards of the Journal of Biomedical Materials Research: Part A and Organogenesis. He is a member of the Scientific Advisory Board of Acuitive Technologies, Inc. and was the co-founder of several medical device companies in the areas of dialysis, vascular surgery, and orthopedic surgery. Back to top.

 


 

Daniel AndersonDaniel G. Anderson, PhD
Department of Chemical Engineering, Institute for Medical Engineering and Science, Harvard-MIT Division of Health Sciences and Technology; David H. Koch Institute for Integrative Cancer Research

Professor Daniel G. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances and products in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. His work has resulted in the publication of over 300 papers, patents and patent applications. These patents were the basis for the foundation of a number of companies in the pharmaceutical, biotechnology, and consumer products space, and have led to a number of products that have been commercialized or are in clinical development. Back to Top.

 


 

Arnold CaplanArnold Caplan, PhD
Director, Skeletal Research Center; Professor, Departments of Biology, General Medical Sciences (Oncology), Pathology, and Biomedical Engineering, Case Western Reserve University

Arnold I. Caplan, Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University. He received his Ph.D. from The Johns Hopkins University School of Medicine. Dr. Caplan is a national and international scholar focusing on experimentation in the area of musculoskeletal and skin development. He has published over 400 papers and manuscripts and has long been supported by the NIH and other non-profit and for-profit agencies for his efforts in trying to understand the development, maturation and aging of cartilage, bone, skin and other mesenchymal tissues and for his pioneering research on Mesenchymal Stem Cells. Back to top.

 


 

Gabor ForgacsGabor Forgacs, PhD
Professor of Biological Physics, University of Missouri-Columbia; Chief Scientific Officer, Modern Meadows, Inc.

Gabor Forgacs is a theoretical physicist turned bioengineer turned innovator and entrepreneur. His academic affiliations include the George Vineyard Chair in Biophysics at the University of Missouri-­Columbia and the Chanderna-­Stirkey Chair in Theoretical Physics at Clarkson University, where he is also the Scientific Director of the Shipley Innovation Center. He is the scientific founder of Organovo, Inc. and Modern Meadow, Inc. and serves as the Chief Scientific Officer of the latter. He was trained as a physicist at the Roland Eotvos University, Budapest, Hungary. He also has a degree in biology. His research interests and contributions span from topics in theoretical physics to physical mechanisms in early embryonic development. He is the author of over 180 scientific publications and 5 books, in particular the co-­author of the celebrated text in the field, “Biological Physics of the Developing Embryo” that discusses physical mechanisms that guide embryonic development. He applies these mechanisms to build organ structures using bioprinting, a technology he pioneered. Such structures are already used for drug development and testing. The technology has also been adapted to engineer consumer products of animal origin such as leather and meat in environmentally friendly and ethically conscious manner. Dr. Forgacs has been recognized by numerous prizes and awards. In particular, he is a member of the National Academy of Innovators and was named as one of the “100 most innovative people in business in 2010” by FastCompany. Back to top.

 


 

Fordham MeierBeth Fordham-Meier
Principal and Founder, NovoCreation Consulting, LLC

Principal and Founder of NovoCreation Consulting, LLC, providing consulting services in business development and licensing, intellectual property and portfolio optimization and alliance and project management. Certified Licensing Professional with twenty years experience driving business development and IP initiatives and negotiating partnering transactions in public and private biotech and university licensing. Ten years (2003-2013) at Targacept (NASDAQ: TRGT), culminating in the position of VP, Licensing and Intellectual Property, fueling company and pipeline growth by securing billion-dollar R&D and commercialization deals with global pharma partners AstraZeneca and GlaxoSmithKline. Led cross-functional teams to advance and out-license programs and evaluate opportunities to in-license across multiple therapeutic areas, including CNS, immunology, GI/GU, urology and orphan diseases. Negotiated deals to in-license assets from Cornerstone Therapeutics, Yale University, University of South Florida and Wake Forest University. Member, Portfolio Management Committee, piloting portfolio investment and advancement strategies. Chaired IP Committee, driving IP initiatives to secure Targacept's industry-leading nicotinic portfolio (>150 issued and pending patents) and directing IP due diligence. Back to top. 

 


 

HunzkierRosemarie Hunziker, PhD
Director of Tissue Engineering and Regenerative Medicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Rosemarie Hunziker, Ph.D. is the Director of Tissue Engineering and Regenerative Medicine at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) within the National Institutes of Health (NIH) in the US Department of Health and Human Services (DHHS). In that capacity she has programmatic oversight of discovery and applied research grants.

Dr. Hunziker brings a diverse background to this broad sphere of research. After receiving a Bachelor of Science in Microbiology from the Philadelphia College of Pharmacy and Science (now the University of the Sciences in Philadelphia), she set off to study the complex antigenic profile of bovine lymphocytes and earn a Master of Science in Immunogenetics from Ohio State University. Her Ph.D. work with Tom Wegmann at the University of Alberta involved analysis of the cell surface immunogens at the maternal-fetal interface. Post-doctoral training at the Laboratory of Immunology, National Institutes of Allergy and Infectious Diseases (NIAID/NIH) focused on the generation of transgenic mouse models of histocompatibility antigen variants to study mechanisms of immune recognition and tolerance. Rosemarie set up the NIAID's Transgenic Mouse Facility at the FCRDC in Fort Dietrick, MD to supply intramural scientists with mouse lines engineered to express their protein of choice. After organizing and running that effort for seven years, she left NIH to join the Advanced Technology Program (ATP) at the National Institute of Standards and Technology (NIST, Department of Commerce). ATP awarded grants to for-profit companies for high-risk R&D. There she was a Program Manager in the Chemistry and Life Science Office, with responsibilities to monitor and advance the life science portfolio, with particular emphasis on Tissue Engineering.

After a brief stint in private consulting advising biotechnology companies on strategic use of federal research grants to advance their business goals, Rosemarie returned to NIH in 2004 to help accelerate technology transfer at the National Institute of Dental and Craniofacial Research (NIDCR) and oversee the Dental Biomaterials portfolio. In January, 2007 she moved to her current position at the NIBIB. She is committed to nurturing discovery science and realizing the practical benefits of the exciting developments at the forefront of cell-based tools and therapies. Back to top.

 


 

John JacksonJohn Jackson, PhD
Associate Professor, Wake Forest Institute for Regenerative Medicine

Dr. John D. Jackson is an Associate Professor in the Institute for Regenerative Medicine at Wake Forest School of Medicine. He received his Ph.D. degree in Medical Sciences (Experimental Hematology) from the University of Nebraska Medical Center. He served as Technical Director of the Cell Processing Laboratory at the University of Nebraska Medical Center which provided support for the bone marrow transplantation program. His research interests are in the area of stem cell biology with particular emphasis on the use of stem cell populations in tissue and organ regeneration. He is a member of Tissue Engineering and Regenerative Medicine International Society (TERMIS). Back to top.

 


 

KingNancy King, JD
Co-Director, Center for Bioethics, Health and Society, Wake Forest University

Nancy M. P. King, JD, is Professor, Department of Social Sciences and Health Policy and Wake Forest Institute for Regenerative Medicine at Wake Forest School of Medicine, and Co-Director of the Center for Bioethics, Health, and Society and the Graduate Program in Bioethics at Wake Forest University. Her scholarship addresses a range of bioethics issues, including: informed consent in health care and research; medical decisions at the beginning and end of life; the development and use of experimental technologies; preclinical and animal research; international and cross-cultural questions in human subjects research; benefit and uncertainty in human subjects research; ethical issues in large-scale genetic research and biobanking, gene transfer research, and regenerative medicine; and connections between science, ethics, design, and policy in biotechnology research. She has published over 100 scholarly articles and book chapters, and is co-editor of The Social Medicine Reader (2nd ed., Duke University Press, 2005), Beyond Regulations: Ethics in Human Subjects Research (UNC Press 1999), and Bioethics, Public Moral Argument, and Social Responsibility (Routledge 2012). She has served on hospital ethics committees, IRBs, DSMBs and the NIH Recombinant DNA Advisory Committee, and has taught research ethics in national and international settings. Back to top. 

 


 

KurtzbergJoanne Kurtzberg, MD
Director, Pediatric Blood and Marrow Transplant Program, Duke University Medical Center 

Dr. Joanne Kurtzberg is an internationally renowned expert in pediatric hematology/oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and novel applications of cord blood in the emerging fields of cellular therapies and regenerative medicine. Dr. Kurtzberg pioneered the use of umbilical cord blood as an alternative stem cell source for unrelated hematopoietic stem cell transplantation (HSCT). Over the last two decades Dr. Kurtzberg has established an internationally known pediatric transplant program at Duke which treats children with cancer, blood disorders, immune deficiencies, hemoglobinopathies and inherited metabolic diseases. In 2010, Kurtzberg established the Julian Robertson Cell and Translational Therapy Program (CT2) at Duke. CT2 focuses on translational studies from bench to bedside with a focus on bringing cellular therapies in regenerative medicine to the clinic. Recent areas of investigation in CT2 include the use of autologous cord blood in children with neonatal brain injury and cerebral palsy, as well as preclinical studies manufacturing oligodendrocyte-like cells from cord blood to treat patients with acquired and genetic brain diseases. Studies of autologous bone marrow ALDHbright cells in adults with stroke and radiation induced brain injury are also underway. Plans are ongoing to extend this work to the use of autologous cord blood in a study of young children with Autism Spectrum Disorder.

Dr. Kurtzberg established one of the largest unrelated donor cord blood bank, the Carolinas Cord Blood Bank, in the world at Duke in 1998. The bank has a current inventory of >40,000 units and has provided cord blood units to over 2,200 patients undergoing unrelated donor HSCT over the past 10 years. Dr. Kurtzberg’s lab has developed novel assays to predict cord blood potency from segments attached to cryopreserved cord blood units, and is performing translational research testing cord blood expansion, cellular targeted therapies and tissue repair and regeneration. In 2012, under the direction of Dr. Kurtzberg, the Carolinas Cord Blood Bank received FDA approval for DuCord, a stem cell product derived from umbilical cord blood, for use in transplants between unrelated donors and recipients. Dr. Kurtzberg currently holds several INDs for investigational clinical trials.

Dr. Kurtzberg has published over 300 peer-reviewed papers, multiple chapters and scientific reviews. She is a member of the American Society of Hematology, the American Association of Blood and Marrow Transplantation, the American Society of Pediatric Hematology/Oncology, the International Society of Cellular Therapies, the Pediatric Blood and Marrow Transplant Consortium (PBMTC), and other organizations. She serves on the Board of the Foundation of Accreditation of Cellular Therapies, co-chairs the National Marrow Donor Program’s Cord Blood Advisory Group and is a member of the Advisory Council of Blood Stem Cell Transplantation to Health and Human Services. Dr. Kurtzberg was awarded a Lifetime Achievement Award from the PBMTC in 2012. Back to top.

 


 

Jeanne F. Loring, PhD
Professor of Developmental Neurobiology, Director of the Center for Regenerative Medicine, Department of Chemical Physiology, California Campus, The Scripps Research Institute

Dr. Loring's research team focuses on large-scale analysis of genomics and epigenetics of human pluripotent stem cells (hPSCs) and their derivatives, in order to ensure the quality and safety of these cells for clinical use. The lab's translational projects include development of cell therapies for Parkinson’s disease, multiple sclerosis, and Alzheimer disease, and epigenetic modeling of autism. In addition to her scientific research, Dr. Loring is committed to educating both scientists and the public. She is particularly concerned with the ethics of stem cell generation and clinical use, the legal implications of stem cell patents, and the dangers of unregulated stem cell treatments (“stem cell tourism”). Back to top.

 


 

MariniFrank Marini, PhD
Professor, Wake Forest Institute for Regenerative Medicine

Dr. Frank Marini, is a stem cell biologist who focuses on identifying stem cells in the development of cancer. His work involves novel non-invasive and invasive imaging techniques to track and identify cells while they participate in wound healing and tumor development. He currently heads the Center for Regenerative Imaging, and is a Professor of Regenerative Medicine and Cancer Biology at Wake Forest Institute for Regenerative Medicine. Back to top.

 


 

Antonios MikosAntonios G. Mikos, PhD
Louis Calder Professor of Bioengineering, Chemical and Biomolecular Engineering, Director for Center for Excellence in Tissue Engineering, Director for J.W. Cox Laboratory for Biomedical Engineering, Rice University

Antonios G. Mikos is the Louis Calder Professor of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He is the Director of the J.W. Cox Laboratory for Biomedical Engineering and the Director of the Center for Excellence in Tissue Engineering at Rice University. His research focuses on the synthesis, processing, and evaluation of new biomaterials for use as scaffolds for tissue engineering, as carriers for controlled drug delivery, and as non-viral vectors for gene therapy. His work has led to the development of novel orthopaedic, dental, cardiovascular, neurologic, and ophthalmologic biomaterials. He is the author of over 550 publications and the inventor of 28 patents.

Mikos is a Member of the National Academy of Engineering, the National Academy of Medicine, the National Academy of Inventors, and the Academy of Athens. He has been recognized by various awards including the Lifetime Achievement Award of the Tissue Engineering and Regenerative Medicine International Society-Americas, the Founders Award of the Society For Biomaterials, and the Robert A. Pritzker Distinguished Lecturer Award of the Biomedical Engineering Society. He is a founding editor and editor-in-chief of the journal Tissue Engineering, and Past-President of the Tissue Engineering and Regenerative Medicine International Society-Americas and the Society For Biomaterials. Back to top.

 


 

C. Randal Mills headshotC. Randal Mills, PhD
President & CEO, California Institute for Regenerative Medicine (CIRM)

C. Randal Mills, Ph.D., is the President & CEO of the California Institute for Regenerative Medicine, the state’s $3 billion stem cell agency. Dr. Mills launched CIRM 2.0, which radically overhauled the way the agency does business. CIRM now has a portfolio of approximately 300 projects in various stages of development from discovery through Phase 3.
 
Previously, Mills served as the CEO of Osiris Therapeutics, taking it public and building it into a profitable stem cell company. Under his leadership Osiris received the world's first approval for a stem cell drug, Prochymal® and commercialized five cell therapy products responsible for more than $1 billion in sales.
 
Mills started his career at the University of Florida Tissue Bank and was a co-founder and a Vice President of Regeneration Technologies where he invented the company’s core technology, BioCleanse®.
 
Mills currently serves on the Board of Directors for Azyio Biologics and Tissue Banks International, and is a member of the Wake Forest Institute of Regenerative Medicine Advisory Board.
 
He earned a Ph.D. in Drug Development and Bachelor's in Microbiology both from the University of Florida. Back to top.

 


 

MurphySean Murphy, PhD
Assistant Professor, Wake Forest Institute for Regenerative Medicine

Sean Murphy received his Ph.D. From Monash University in Australia under the supervision of Profs. Alan Trounson, Euan Wallace and Graham Jenkin. He developed methodologies to isolate and characterize fetal stem cells for clinical applications and demonstrated their potential for treating lung disease. He is currently a postdoctoral research fellow at the Wake Forest Institute for Regenerative Medicine, North Carolina, mentored by Prof. Anthony Atala. His research focuses on developing perinatal stem cell therapies for lung diseases such as cystic fibrosis and is supported by an American Lung Association Senior Research Training Fellowship and a Chapman Foundation grant. Back to top.

 


 

Daniel NelsonDaniel K. Nelson, MS, CIP
Professor and Director of U.S. Environmental Protection Agency and University of North Carolina - Chapel Hill

Dr. Daniel Nelson is Director of the Human Research Protocol Office for the National Health and Environmental Effects Research Lab (NHEERL), U.S. Environmental Protection Agency (EPA). He is also Adjunct Professor of Social Medicine and Pediatrics, and Faculty Associate in the Center for Bioethics at the University of North Carolina-Chapel Hill. Trained in medical physiology, Nelson previously held faculty appointments at the Mayo Clinic, the University of Rochester and UNC-Chapel Hill, where he directed the Institutional Review Boards for 16 years. A national leader in the field of human research protections, Nelson has served as past-president of the Applied Research Ethics National Association (ARENA); charter member of the Council for Accreditation and Site Visitor, Association for the Accreditation of Human Research Protection Programs (AAHRPP); charter member of the Council for Certification of IRB Professionals (CCIP); and consultant to the federal Office for Human Research Protections (OHRP). From 2004-2014, he chaired a subcommittee of the Secretary’s Advisory Committee on Human Research Protections (SACHRP), which advises DHHS on the regulations that govern this area. In 2013 Nelson was honored by Public Responsibility in Medicine and Research (PRIMR) with the ARENA Legacy Award, for leadership and contributions to the field of research ethics. Back to top.

 


 

 Steven Oh headshotSteven Oh, PhD
Chief, Cell Therapies Branch; Office of Cellular, Tissues and Advanced Therapies, FDA, CBER

Dr. Oh is Chief of Cell Therapies Branch which regulates cell-based therapeutic products, tissue-engineered products, combination products, and point-of-care devices having therapeutic or regenerative indications. He is also Acting Deputy Director of Division of Cellular and Gene Therapies. Dr. Oh provides leadership in reaching various regulatory decisions on medical products submitted to Office of Tissues and Advanced Therapies in Center for Biologics Evaluation and Research (CBER) for marketing, clinical investigation, or product classification in the U.S. He is actively involved in the development of regulatory policies for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P’s) and cell-based combination products. He interacts closely with Center for Devices and Radiological Health (CDRH) and Center for Drug Evaluation and Research (CDER) in FDA and with other government agencies on cross-cutting scientific and regulatory issues and policies. Dr. Oh participate in international standards activities in the manufacture and testing of cellular products and tissue-engineered medical products. In addition, Dr. Oh is engaged in various efforts promoting global regulatory convergence in cell-based therapeutic products. Before joining FDA in 2007, Dr. Oh served on the faculty of Tufts University School of Medicine in Boston. He was trained as a cell biologist and biochemist at Massachusetts Institute of Technology, Johns Hopkins University School of Medicine, and the University of Michigan. Back to top.

 


 

PoradaChris Porada, PhD
Associate Professor, Wake Forest Institute for Regenerative Medicine

Dr. Christopher Porada received his Bachelor’s in Molecular Biology from Colgate University in 1991 and his PhD in Cellular and Molecular Pharmacology and Physiology from the University of Nevada in 1998. After completing his PhD, he served as an Assistant and then Associate Professor in the Department of Animal Biotechnology at the University of Nevada, Reno. He has authored over 40 scientific publications and reviews, has written chapters in several books, and served as an Associate Editor for Experimental Hematology. He is a member of several international societies including the American Society of Hematology, the International Society of Experimental Hematology, and the American Society of Gene and Cell Therapy, and regularly reviews for several international journals focused on gene therapy, gene and drug delivery, stem cell biology, and stem cell transplantation. Dr. Porada joined the faculty at WFIRM in 2011. Back to top.

 


 

Bob PretiRobert Preti
Chairman, Alliance for Regenerative Medicine; Director, Caladrius Biosciences

Dr. Preti is the co-Founder of PCT, a Caladrius company, an industry-leading cell therapy contract development and manufacturing organization, and the visionary behind its successful growth and development strategy over much of the last two decades. In addition to his roles at PCT and Caladrius Biosciences, he is also the Chairman for the Alliance for Regenerative Medicine. He has published and presented extensively on a variety of topics relating to cellular therapies and holds a B.S. in Biology from Fordham University, and an M.S. and doctorate from New York University. Back to top.

 


 

 Becky Robinson-ZeiglerBecky Robinson-Zeigler, PhD
Chief of Pharmacology/Toxicology Branch 2 in CBER/OTAT

Becky Robinson-Zeigler is chief of the Pharmacology/Toxicology Branch 2 in the Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT) in the Office of Tissues and Advanced Therapies (OTAT) in the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA). After receiving her PhD in Biomedical Engineering, she joined the FDA in 2010 as a Regenerative Medicine Commissioner’s Fellow, where she conducted scientific review of regulatory applications for medical devices, and cell and gene therapy products. Upon completion of her fellowship in 2012, she joined the Center for Devices and Radiological Health (CDRH) as a scientific reviewer in the Division of Reproductive, Gastro-Renal, and Urological Devices (DRGUD). During her time at CDRH she was actively involved in Center-level projects and received several awards for her work. Dr. Robinson-Zeigler re-joined CBER in 2014 where she supervises regulatory review of pharmacology/toxicology data for a diverse product portfolio, including: chimeric antigen receptor T cells, oncolytic viruses, gene therapy products using gene editing technology, human embryonic stem cells, induced pluripotent stem cells, recombinant therapeutic proteins, fibrin sealants, and regenerative medicine, tissue-engineered, and combination products. Back to top.

 


 

Aleksander SkardalAleksander Skardal, PhD
Assistant Professor, Wake Forest Institute for Regenerative Medicine

Aleksander Skardal received his B.Sc. from Johns Hopkins University in 2005 and his Ph.D. from the University of Utah in 2010. He joined the Wake Forest Institute for Regenerative Medicine in 2010 initially focusing on the application of hydrogel biomaterials for wound healing cell therapies and fabrication of environments for modulating stem cell behaviors and primary cell viability and function in vitro. His current research continues to apply hydrogel biomaterials within the framework of several areas including: biofabrication of microtissue "organoids" for diagnostics (aka "Body-on-a-Chip"), host tissue organoids for in vitro modeling of metastasis phenomena and mechanisms, integration with microfluidic systems, and naturally-derived hydrogels for cell-free wound healing therapies. Back to top.

 


 

Igor SlukvinIgor Slukvin, MD, PhD
Professor, Department of Pathology and Laboratory Medicine, University of Wisconsin

Dr. Igor Slukvin, MD, PhD is a Professor of Pathology and Laboratory Medicine and Cell and Regenerative Biology at the University of Wisconsin, Madison. He is also director of Precision Medicine Core at Wisconsin National Primate Research Center. His research interest is in the understanding of cellular and molecular pathways leading to development of hematopoietic and vasculogenic cells from human embryonic and induced pluripotent stem cells (iPSCs). His work is relevant for the development of novel sources of cells for bone marrow transplantation, transfusion and cancer immunotherapy. Currently his laboratory focuses on 1) identifying of genes essential for acquisition of long-term engraftment potential by hematopoietic cells emerging from PSC-derived hemogenic endothelium; 2) establishing a non-human primate model of iPSC-based cellular therapy for blood and immune system disorders; 3) developing iPSC based models for blood cancer stem cell development; 4) defining cellular and molecular pathways leading to formation of vasculogenic cells from human PSCs. Back to top.

 


 

Doris TaylorDoris A. Taylor, PhD, FAHA, FACC
Director, Regenerative Medicine Research, Texas Heart Institute; Director, Center for Cell and Organ Biotechnology at Texas Heart Institute and TAMU College of Veterinary Medicine

Dr. Doris A. Taylor directs Regenerative Medicine Research at Texas Heart Institute (THI) in Houston, Texas as well as the Center for Cell and Organ Biotechnology, a collaboration between THI and Texas A&M University. Her research interests include cell and gene therapy for treatment of cardiovascular disease, sex differences in cardiac and vascular cell-based therapy, tissue engineering of bio-artificial organs and vasculature, cell-based prevention of disease, stem cells and cancer, aging as a failure of stem cells, and complementary and alternative approaches to endogenous (cell-mediated) repair. She is a dedicated educator with more than 25 years of teaching experience and mentoring.

Dr. Taylor is a globally recognized scientist credited with a number of important scientific breakthroughs related to cell therapy, stem cell biology, and tissue-engineering-based therapies. She holds a number of invention disclosures, patent applications, and patents and is the founder of multiple companies dedicated to cardiovascular repair technologies. As a pioneer in cardiovascular cell therapy, Dr. Taylor’s mechanistic insights and effective approaches to cardiac repair and replacement are well established and include a number of firsts. She holds many awards and honors, including appointments as a Fellow for the American Heart Association Council on Functional Genomics and Translational Biology and the American College of Cardiology Council on Basic Cardiovascular Sciences. She has been recognized by the AHA for Top 10 Research Advances and serves on numerous international scientific think-tanks and as a member of the Institut de France LeFoulon-Delalande Grand Prix jury that awards a half-million Euros annually to individuals making worldwide contributions to cardiovascular medicine. In 2015, she was honored by her alma mater, Mississippi University for Women, with an honorary doctorate.

Dr. Taylor appears frequently as an expert on stem cell therapy and cardiac repair in the public media as well as the scientific arena. Her work has been recognized and featured by 60 Minutes, CNN, The New York Times, The Wall Street Journal, BBC Horizon, BBC News Health, ABC News, NBC News, CBS News, Associated Press, National Public Radio, Good Morning America, Forbes, the Oprah Winfrey Show, NOVA Science Now, Discovery Channel’s Through the Worm Hole with Morgan Freeman, Science Channel’s Stem Cell Universe with Stephen Hawking, The National Post (Canada), and numerous other worldwide media outlets.

Before joining THI in 2012, Dr. Taylor served as Associate Professor, Division of Cardiology, at Duke University Medical Center and as Medtronic Bakken Professor of Integrative Biology and Physiology and Director of the Center for Cardiovascular Repair at the University of Minnesota. She is a member of the Society for Women’s Health Research (SWHR) and served as co-chair of the NHLBI Sex Bias in Cardiovascular Research Working Group. She is also a member of the Organization for the Study of Sex Differences (OSSD). Other professional affiliations include: The American Association for the Advancement of Science (AAAS); American Physiological Society (APS); Biophysical Society; AHA Council on Basic Cardiovascular Sciences; Federation of American Societies for Experimental Biology (FASEB); International Society for Applied Cardiovascular Biology (ISACB); Tissue Engineering Council; and the International Society for Heart & Lung Transplantation (ISHLT).

Dr. Taylor has served as an advisor to a number of national committees, including the FDA Cellular, Tissue and Gene Therapies Advisory Committee, Department of Health and Human Services, 2005-2010. She currently serves as a consulting member to the FDA Research Review Sub-Committee for Cellular, Tissue and Gene Therapies Advisory Board (Bethesda, Maryland), the American Association of Blood Banks Standards Committee, and the American Society for Gene Therapy. She was recently appointed to the Board and Executive Committee for the Alliance for Regenerative Medicine (ARM). Back to top.

 


 

Omid VeisehOmid Veiseh, PhD
Assistant Professor and CPRIT Scholar in Cancer Research, Department of Bioengineering, Rice University

Dr. Omid Veiseh is an Assistant Professor and CPRIT Scholar in Cancer Research in Department of Bioengineering at Rice University. His laboratory utilizes advanced nano-, micro-, and macro- fabrication techniques in combination with molecular engineering and cellular and molecular biology, to develop platforms of implantable devices tailored for in vivo chemical sensing and delivery of therapeutics. Dr. Veiseh received a dual Ph.D. in Materials Science, Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Prof. Daniel Anderson at Koch Institute for Integrative Cancer Research at MIT and Harvard Medical School. Over the course of his career he has authored, or co-authored more than 50 peer-reviewed publications including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, Nature Reviews Drug Discovery, and is an inventor on 20 pending or awarded patents, many of which have been licensed for commercialization by 3 separate biotechnology companies. He has received numerous awards and fellowships including: NSF Integrative Graduate Education and Research Training (IGERT) Fellowship, NIH T32 Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship, Juvenile Diabetes Research Foundation Postdoctoral Fellowship, DOD/CDMRP Breast Cancer Research Program Postdoctoral Fellowship, and DOD/CDMRP Visionary Postdoctoral Fellowship, a Young Investigator Award from the Arthritis National Research Foundation (ANRF), and most recently, he was awarded a $2 million CPRIT Scholar In Cancer Research Award from state of Texas. Back to top.

 


 

Julie Watson(2)Julie Watson, JD
Special Counsel, Marshall, Gerstein & Borun, LLP; Intellectual Property Director and Legal Counsel, WFIRM

Julie M. Watson, special counsel at Marshall Gerstein & Borun LLP, concentrates on counseling related to intellectual property transactions with a particular emphasis in technology startups and university technology transfer. A licensing professional with over 25 years experience structuring complex intellectual property transactions in-house, Ms. Watson has a deep appreciation of clients’ needs and knows how to deliver strategic solutions. Ms. Watson manages the intellectual property program for the Wake Forest Institute for Regenerative Medicine, where she served as director of intellectual property and legal counsel prior to joining Marshall Gerstein & Borun. Ms. Watson holds a J.D., cum laude, from Wake Forest University Law School and is admitted to practice law in Illinois, North Carolina and before the USPTO. She holds an MA from Johns Hopkins University and is a Certified Licensing Professional™ (CLP), a credential issued by the Licensing Executives Society (LES) (USA and Canada), Inc. Ms. Watson is a frequent speaker and active participant in professional licensing organizations and has authored more than 50 national presentations and publications including peer-reviewed articles. Back to top.

 


 

WilliamsDavid Williams, DSc
Professor and Director of International Affairs, Wake Forest Institute for Regenerative Medicine

Professor Williams has had 45 years experience in biomaterials, medical device and tissue engineering. During his career he has published over 30 books and 400 papers: his latest book, Essential Biomaterials Science will be published by Cambridge University Press in June 2014. He has been Editor-in-Chief of Biomaterials, the world’s leading journal in this field since 2000. He has received the major awards from the US, European and Indian societies of biomaterials including the Founders Award of the US Society for Biomaterials in 2007, and received the prestigious Acta Biomaterialia Gold Medal in 2012. In 1999 he was elected as a Fellow of the Royal Academy of Engineering and is a Foreign Fellow of the Indian National Academy of Engineering and a Fellow of the American Institute of Medical and Biological Engineering, all in recognition of his contributions to engineering in medicine. He is currently global President of the Tissue Engineering & Regenerative Medicine International Society.

Professor Williams left the University of Liverpool, UK, in 2007, where he had been Head of Clinical Engineering, Director of the UK Centre for Tissue Engineering and Pro Vice Chancellor of the University. While retaining the title of Emeritus Professor at Liverpool, he is currently Professor and Director of International Affairs, Wake Forest Institute of Regenerative Medicine, North Carolina, USA. In addition, he is a Visiting Professor in the Christiaan Barnard Department of Cardiothoracic Surgery, Cape Town, South Africa, a Visiting Professorial Fellow at the Graduate School of Biomedical Engineering, University of New South Wales, Australia, and a Guest Professor, at Tsinghua Universities, Beijing, and Advisory Professor at Shanghai Jiao Tong University, China. He is Visiting Chair Professor of Biomedical Materials, Taipei Medical University, Taiwan. In Cape Town, along with Professor Peter Zilla, the current Chris Barnard Professor of Surgery, he has formed a company that will produce low cost but high technology medical devices that can be used with minimally invasive procedures to treat young adults in sub-Sarah Africa, who currently have no therapies available to them. Back to top.

 


 

YooJames J. Yoo, MD, PhD
Associate Director and Chief Scientific Officer, WFIRM

Dr. Yoo is a surgeon and researcher. He is currently a faculty member at the Wake Forest Institute for Regenerative Medicine and is cross-appointed to the Department of Urology, Physiology and Pharmacology, and Biomedical Engineering. Dr. Yoo received his Bachelor’s Degree in biology from the University of Illinois in 1984. Back to top.

























 

 

 

 

Quick Reference

Institute for Regenerative Medicine

Phone 336-713-7293
Fax 336-713-7290

Location
Richard H. Dean Biomedical Building
391 Technology Way
Winston-Salem, NC 27101
Find A Doctor Ways to Give
Last Updated: 02-10-2017
Five Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is RenewedMagnet Hospital Recognition2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.